Treatment of T2D patients with rapalogs is dubious in light of their side effects [182], and since chronic treatment may result in inhibition of mTORC2, thereby suppressing the IR-Akt transduction pathway. The gene discussed is AKT1; the disease is type 2 diabetes mellitus.